Bioplus-Interphex brings together Korean, U.S. biotech experts for discussion

[Image captured from COEX homepage]

Biotech and pharmaceutical companies and experts from South Korea and the U.S. are coming together at Bioplus-Interphex Korea 2023 (BIX), the largest domestic exhibition and convention event in the biotech field.

BIX aims to showcase the biopharmaceutical value chain and propose strategies for expanding overseas by establishing global business networks.

The Ministry of Trade, Industry, and Energy said on Wednesday that it will support collaboration between Korean and American biotech companies at the BIX event organized by the Korea Biotechnology Industry Organization (Korea BIO). The exhibition, which kicked off Wednesday, will be held at COEX in Seoul until July 14.

The gathering comes just a month after representatives from the Korean and American bio industries gathered in Boston, U.S.

BIX is an international event that attracts some 10,000 participants, including Korean companies like Samsung Biologics Co., Celltrion Inc., and SK bioscience Co. Global contract development and manufacturing organizations (CDMOs) such as Lonza, WuXi, and Fuji are also participating.

On Thursday, Nancy Travis, vice president for International Affairs at the Biotechnology Innovation Organization (BIO), will hold a conference on the topic of U.S. biotechnology and manufacturing executive orders and “Bio USA 2023 Debriefing.”

The Korea BIO previously signed a memorandum of understanding with its American counterpart, BIO, following President Yoon Suk Yeol’s state visit to the U.S. in April. Last month, the organization also attended the BIO USA Convention hosted by BIO in Boston.

During the BIO USA event, the government co-hosted a “Korea-U.S. BIO Roundtable” in collaboration with the Korea BIO.